In a recent CRISPR Medicine News article, the CEO of Demeetra Jack Crawford says, “many of the 120+ cannabinoids already produced naturally in cannabis [are] not produced at levels sufficient for R&D and commercial manufacture. There are also significant opportunities to enhance natural cannabinoids for therapeutic purposes using gene editing in combination with synthetic biotechnology … we are working to build a platform of virtually unlimited bioproduct candidates. “
Demeetra leverages its precision gene editing tools in combination with traditional breeding techniques to manufacture specialized plants and other bioprocessing systems that produce targeted therapeutic cannabinoids. It uses a synthetic biotechnology approach in yeast to produce very rare and new cannabinoid-like molecules. Demeetra is also developing processes to manufacture large-scale biotherapeutics, using Chinese hamster ovary (CHO) and yeast cell lines as bioprocess platforms. Demeetra has partnered with large pharmaceutical companies and subcontractors in the field of biotherapy.
Demeetra is advancing a therapeutic cannabinoid pipeline and plans to file an IND in the first quarter of 2022 for its lead candidate. “We have built a very robust in-house manufacturing and processing using the cannabis plant where we consistently get a 20% yield in the plant and then isolate at 99.9% purity on a kilogram scale. ”Said Crawford. “There is literally unlimited potential here.”
Crawford added: “What we are missing are processes for successful gene editing in the cannabis plant and we believe this will require some collaboration with experts in cannabis genomics.” Demeetra is currently seeking collaboration opportunities to achieve this goal. For more information, please contact Demeetra’s business development group, The Workdom Team [email protected].
SOURCE Demeetra AgBio